Radioimmunotherapy of Medullary Thyroid Cancer with Iodine-131-Labeled Anti-CEA Antibodies

Journal of Nuclear Medicine

Volumn 37, Issue 6, 1996, Pages 905-911

  Juweid, Malik ^b   Sharkey, Robert M ^b   Behr, Thomas ^b   Swayne, Lawrence C ^b   Herskovic, Thomas ^b   Pereira, Michael ^b   Rubin, Arnold D ^b   Hanley, Debra ^b   Dunn, Robert ^b   Siegel, Jeffry ^b   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b NONE

Author keywords

Carcinoembryonic antigen; Medullary thyroid cancer; Monoclonal antibodies; Radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HUMAN; IMMUNOLOGY; MALE; MEDULLARY CARCINOMA; MIDDLE AGED; RADIATION DOSE; RADIOIMMUNOTHERAPY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, MEDULLARY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030163020     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rossi RL, Cady B, Meissner WA, Wool MS, Sedgwick CE, Werber J. Nonfamilial medullary thyroid carcinoma. Am J Surg 1980;139:554-560.
2. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67:801-808.
3. Schroder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry and DNA content. Cancer 1988;61:806-816.
4. Norton JA, Levin B, Jensen R. Cancer of the endocrine system. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practices of oncology. New York: JB Lippincott Co; 1989:1333-1435.
5. Cance WG, Wells SA Jr. Multiple endocrine neoplasm type IIa. Curr Probl Surg 1985;22:1.
6. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancer. Cancer 1985;55:2062-2071.
7. Wells SA Jr, Dilley WG, Farndon JA, Leight GS, Baylin SB. Early diagnosis and treatment of medullary carcinoma. Arch Intern Med 1985;145:1248-1252.
8. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-285.
9. Ishikawa N, Hamada S. Association of medullary carcinoma of the thyroid with carcinoembryonic antigen. Br J Cancer 1976;34:111-115.
10. Wells SA Jr, Haagensen DE Jr, Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer 1978;42:1498-1503.
11. Rougier PH, Calmettes C, Laplanche A, et al. The values of calcitonin and carcinoembryonic antigen in the treatment and management of nonfamilial medullary thyroid carcinoma. Cancer 1983;51:855-862.
12. Juweid M, Sharkey RM, Behr T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209-1217.
13. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: Antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-692.
14. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-3485.
15. Sharkey RM. Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high-affinity, anticarcinoembryonic-antigen-specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2082-2096.
16. Sharkey RM, Goldenberg DM, Goldenberg H, et al. Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans. Cancer Res 1990;50:2823-2831.
17. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34(2):261-264.
18. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039s-1042s.
19. 131I-labeled LL2 (EPB2) monoclonal antibody in patients with B-cell lymphomas. Antibod Immunoconj Radiopharm 1991;4:649-654.
20. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide. MIRD pamphlet no. I, revised. New York: Society of Nuclear Medicine; 1976.
21. Bigler R, Zanzonico PB, Leonard R, et al. Bone marrow dosimetry for monoclonal antibody therapy. Proceeding of the 4th International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, TN: 1985:535-544.
22. Cloutier RV, Watson EE, Rohrer RH, et al. Calculating the radiation dose to an organ. J Nucl Med 1973;14:53-55.
23. Peltier P, Curtet C, Chatal JE, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993;34:1267-1273.
24. 2 fragments of anticarcinoembryonic antigen monoclonal antibody for detecting recurrences of medullary thyroid carcinoma. J Clin Endocrinol Metab 1992;74:157-163.
25. Edington HD, Watson CG, Levine G, et al. Radioimmunoimaging of metastatic medullary carcinoma of the thyroid gland using an indium-111-labeled monoclonal antibody to CEA. Surgery 1988;104:1004-1010.
26. Zanin DEA, van Dongen A, Hoefnagel CA, Bruning PF. Radioimmunoscintigraphy using iodine-131-anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report. J Nucl Med 1990;31:1854-1855.
27. 111In-labeled monoclonal anti-CEA antibody fragment. Nuklearmedizin 1986;25:227-231.
28. Behr T, Sharkey RM, Juweid M, et al. Influence of antibody protein on the dosimetry and diagnostic accuracy in radioimmunodetection (RAID) and therapy (RAIT) of CEA-expressing tumors [Abstract]. J Nucl Med 1995;36:226.
29. 111In-labeled mouse antimelanoma monoclonal antibody ZME-018. J Nucl Med 1987;28:25-33.
30. 111In-labeled monoclonal antitumor antibodies: kinetics, biodistribution and tumor detection. Radiology 1988;168:529-536.
31. 111In-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. J Clin Oncol 1988;6:1220-1230.